Expression and clinical significance of RCDG1 in renal cell carcinoma: A novel renal cancer‑associated gene

Yu,Zuhu; Ni,Liangchao; Chen,Duqun; Su,Zhengming; Yu,Wenshui; Zhang,Qiang; Wang,Yadong; Li,Cailing; Gui,Yaoting; Lai,Yongqing

doi:10.3892/mmr.2014.2388

Expression and clinical significance of RCDG1 in renal cell carcinoma: A novel renal cancer‑associated gene

Authors:
- Zuhu Yu
- Liangchao Ni
- Duqun Chen
- Zhengming Su
- Wenshui Yu
- Qiang Zhang
- Yadong Wang
- Cailing Li
- Yaoting Gui
- Yongqing Lai
View Affiliations

Affiliations: Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China, The Key Laboratory of Stem Cell Biology, Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
Published online on: July 16, 2014 https://doi.org/10.3892/mmr.2014.2388
Pages: 1583-1589

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recently identified molecular tumor markers have numerous potential applications in the diagnosis, therapy and prognostic prediction of renal cell carcinoma (RCC). Through bioinformatics‑based screening approaches together with validation of western blot and immunohistochemical data, the present study identified a novel renal cancer‑associated gene, preliminarily named Renal Cancer Differentiation Gene 1 (RCDG1), originally known as chromosome 4 open reading frame 46 (C4orf46). RCDG1 expression was evaluated by western blot analysis of RCC and adjacent normal tissues, renal cancer cell lines and normal kidney HEK293T cells. Additionally, RCDG1 expression was assessed in 124 RCC paraffin sections, including 92 paired adjacent normal tissues, by immunohistochemistry. The results showed that RCDG1 was significantly downregulated in RCC tissues as compared with normal adjacent tissues (P<0.001), and the expression of RCDG1 in clear cell (cc) RCC tissues was significantly lower as compared with that of non‑ccRCC tissues (P=0.005). Furthermore, statistical analysis revealed RCDG1 expression was negatively correlated with the Fuhrman grade in ccRCC (P=0.008). A reduction in RCDG1 expression may be associated with the oncogenesis of RCC and the differentiation of ccRCC. Further studies may provide more information about the function of RCDG1 gene in RCC.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Patel C, Ahmed A and Ellsworth P: Renal cell carcinoma: a reappraisal. Urol Nurs. 32:182–190. 2012.PubMed/NCBI
3	Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar
4	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
5	Jiang Z, Chu PG, Woda BA, et al: Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 7:556–564. 2006. View Article : Google Scholar : PubMed/NCBI
6	Suh JH, Oak T, Ro JY, Truong LD, Ayala AG and Shen SS: Clinicopathologic features of renal cell carcinoma in young adults: a comparison study with renal cell carcinoma in older patients. Int J Clin Exp Pathol. 2:489–493. 2009.PubMed/NCBI
7	Lopez-Beltran A, Scarpelli M, Montironi R and Kirkali Z: 2004 WHO classification of the renal tumors of the adults. Eur Urol. 49:798–805. 2006. View Article : Google Scholar : PubMed/NCBI
8	Cheville JC, Lohse CM, Zincke H, Weaver AL and Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 27:612–624. 2003. View Article : Google Scholar : PubMed/NCBI
9	Choi YD, Kim KS, Ryu S, et al: Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. J Korean Med Sci. 22:305–310. 2007. View Article : Google Scholar : PubMed/NCBI
10	Fu L, Wang G, Shevchuk MM, Nanus DM and Gudas LJ: Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. Cancer Res. 73:2916–2925. 2013.
11	Metcalf JL, Bradshaw PS, Komosa M, Greer SN, Stephen Meyn M and Ohh M: K63-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair. Oncogene. 20:1055–1065. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhang N, Wu P, Wu L, et al: The differential expression of vascular endothelial growth inhibitor isoforms, VEGI251, VEGI174 and VEGI192 in human clear-cell renal cell carcinoma. Cancer Genomics Proteomics. 10:47–53. 2013.
13	Wood CG: Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy. J Surg Oncol. 94:264–265. 2006. View Article : Google Scholar
14	Fritzsche FR, Riener MO, Dietel M, Moch H, Jung K and Kristiansen G: GOLPH2 expression in renal cell cancer. BMC Urol. 8:152008. View Article : Google Scholar : PubMed/NCBI
15	Tsimafeyeu I, Demidov L, Stepanova E, Wynn N and Ta H: Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol. 45:190–195. 2011. View Article : Google Scholar : PubMed/NCBI
16	Cairns P: Renal cell carcinoma. Cancer Biomark. 9:461–473. 2010.
17	Lai Y, Yu Z, Wang Y and Ye J: Identification of PCAG1 as a novel prostate cancer-associated gene. Mol Med Rep. 7:755–760. 2013.PubMed/NCBI
18	Krizman DB, Wagner L, Lash A, Strausberg RL and Emmert-Buck MR: The Cancer Genome Anatomy Project: EST sequencing and the genetics of cancer progression. Neoplasia. 1:101–106. 1999. View Article : Google Scholar : PubMed/NCBI
19	Sun S, Du R, Gao J, et al: Expression and clinical significance of Notch receptors in human renal cell carcinoma. Pathology. 41:335–341. 2009. View Article : Google Scholar : PubMed/NCBI
20	Maaser K, Daubler P, Barthel B, et al: Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis. Br J Cancer. 88:1217–1222. 2003. View Article : Google Scholar : PubMed/NCBI
21	Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
22	Lam JS, Pantuck AJ, Belldegrun AS and Figlin RA: Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin Cancer Res. 13:703s–708s. 2007. View Article : Google Scholar : PubMed/NCBI
23	Chuang MJ, Sun KH, Tang SJ, et al: Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci. 99:905–913. 2008. View Article : Google Scholar
24	Linehan WM, Lerman MI and Zbar B: Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA. 273:564–570. 1995. View Article : Google Scholar : PubMed/NCBI
25	Schraml P, Struckmann K, Hatz F, et al: VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol. 196:186–193. 2002. View Article : Google Scholar : PubMed/NCBI
26	Bui MH, Seligson D, Han KR, et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 9:802–811. 2003.PubMed/NCBI
27	Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ and Oosterwijk E: Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 58:75–83. 2010. View Article : Google Scholar
28	Di Cello F, Shin J, Harbom K and Brayton C: Knockdown of HMGA1 inhibits human breast cancer cell growth and metastasis in immunodeficient mice. Biochem Biophys Res Commun. 2013.PubMed/NCBI
29	Loyd CM, Diaconu D, Fu W, et al: Transgenic overexpression of keratinocyte-specific VEGF and Ang1 in combination promotes wound healing under nondiabetic but not diabetic conditions. Int J Clin Exp Pathol. 5:1–11. 2012.